About the Authors
- Hui Mao
-
Current address: Department of Respiratory Medicine, West China Hospital of Sichuan University, Chengdu, China
Affiliation Division of Allergy and Clinical Immunology, Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America
- Gen Kano
-
Affiliation Division of Allergy and Immunology, Cincinnati Children’s Hospital Medical Center and University of Cincinnati College of Medicine, Cincinnati, Ohio, United States of America
- Sherry A. Hudson
-
Affiliation Division of Allergy and Clinical Immunology, Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America
- Mary Brummet
-
Affiliation Division of Allergy and Clinical Immunology, Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America
- Nives Zimmermann
-
Affiliation Division of Allergy and Immunology, Cincinnati Children’s Hospital Medical Center and University of Cincinnati College of Medicine, Cincinnati, Ohio, United States of America
- Zhou Zhu
-
Affiliation Division of Allergy and Clinical Immunology, Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America
- Bruce S. Bochner
-
* E-mail: bbochner@jhmi.edu
Affiliation Division of Allergy and Clinical Immunology, Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America
Competing Interests
The authors have read the journal’s policy and have the following conflicts: Dr. Bochner is a co-inventor on existing and pending Siglec-8-related patents. Dr. Bochner may be entitled to a share of royalties received by the University on the potential sales of such products. Dr. Bochner is also a co-founder of, owns stock in, and is on the scientific advisory board of Allakos, Inc., a company focusing on the development of Siglec-8- directed therapies, which makes him subject to certain restrictions under University policy. The terms of this arrangement are being managed by the Johns Hopkins University in accordance with its conflict of interest policies. None of the other authors have any competing interests. There are no further patents, products in development or marketed products to declare. This does not alter the authors’ adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors. Patents issued: US Patent #6,146,845 (issued 11/14/2000) “Polynucleotides encoding a Sialoadhesin Family, Member-2 (SAF-2)”, US Patent #7,214,772 (issued 5/8/2007) “Sialoadhesin Factor-2”, US Patent #7,557,191 (issued 7/7/2009) “Sialoadhesin Factor-2 Antibodies”, US Patent #7,745,421 (issued 6/29/2010) “Methods and compositions for treating diseases and disorders associated with Siglec-8 expressing cells”, US Patent #7,871,612 (issued 1/18/2011) “Methods of use of Sialoadhesin Factor-2 Antibodies”, Japan Patent #4860877 (issued 11/11/2011) “Sialoadhesin Factor-2 Antibodies”, US Patent #8,178,512 (issued 5/15/2012) “Methods and compositions for treating diseases and disorders associated with Siglec-8″, US Patent #8,197,811 (issued 6/12/2012) “Sialoadhesin Factor-2 Antibodies”, US Patent #8,207,305 (issued 6/26/2012) “Sialoadhesin Factor-2 Antibodies”. Patents pending: Pub. No.: WO/2001/066126; International Application PCT/US2001/007193; Publication Date: 9/13/2001 “Sialoadhesin Factor-2 Antibodies”, European Patent Application #01914720.6, submitted 3/7/2000 “Sialoadhesin Factor-2 Antibodies.
Author Contributions
Conceived and designed the experiments: HM NZ ZZ BSB. Performed the experiments: HW GK SAH MB. Analyzed the data: HM GK SAH MB NZ ZZ BSB. Contributed reagents/materials/analysis tools: ZZ. Wrote the paper: HM GK NZ BSB.